Search This Blog

Thursday, April 9, 2020

JPMorgan halts non-government guaranteed small business loans

A JPMorgan (NYSE:JPM) spokesperson spins it as the bank devoting all resources to processing loan requests under the government’s hastily put-together Paycheck Protection Program.
A cynic might note that the PPP scheme is turning into a nice profit center for the banks, and that the loans are fully guaranteed by the government. Why bother underwriting anything else – particularly if you expect declining asset values and a wave of bankruptcies soon to flood the U.S. court system.
https://seekingalpha.com/news/3559653-jpmorgan-halts-non-government-guaranteed-small-business-loans

Fed fires up another $2.3T of loans to keep credit flowing

The Fed adds new programs to assist households and employers and bolster the ability of state and local governments to deliver critical services during the coronavirus pandemic.
Actions include:
Bolstering the effectiveness of the Small Business Administration’s Paycheck Protection Program (PPP) by supplying liquidity to participating financial institutions through term financing backed by PPP loans to small businesses;
Ensure credit flows to small and mid-sized businesses with the purchase of up to $600B in loans through the Main Street Lending Program. The Department of the Treasury, using funding from the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) will provide $75B in equity to the facility;
Expanding the size and scope of the Primary and Secondary Market Corporate Credit Facilities (PMCCF and SMCCF) as well as the Term Asset-Backed Securities Loan Facility (TALF). These three programs will now support up to $850B in credit backed by $85B in credit protection provided by the Treasury; and
Establishing a Municipal Liquidity Facility that will offer up to $500B in lending to states and municipalities. The Treasury will provide $35B of credit protection to the Federal Reserve for the Municipal Liquidity Facility using funds appropriated by the CARES Act.
Update at 8:42 AM: The Main Street facility will offer four-year loans to companies employing up to 10K workers or with revenue of less than $2.5B. Principal and interest payments will be deferred for one year.
Eligible banks may originate new Main Street loans or use Main Street loans to boost the size of existing loans to businesses. Banks will retain a 5%, selling the remaining 95% to the Main Street facility, which will buy up to $600B of loans.
https://seekingalpha.com/news/3559646-fed-fires-up-another-2_3t-of-loans-to-keep-credit-flowing

More Covid-19 related activity

LabCorp (NYSE:LH) is partnering with Ciox Health on a U.S.-based COVID-19 patient data registry aimed at expediting diagnoses and treatments.
Arcturus Therapeutics (NASDAQ:ARCT) will initiate a study this summer for its COVID-19 vaccine candidate LUNAR-COV19.
CareDx (NASDAQ:CDNA) has mobilized 10K phlebotomists for home blood draws for routine transplant tests in response to the pandemic.
Theravance Biopharma (NASDAQ:TBPH) is advancing TD-093, a lung-selective nebulized Janus kinase inhibitor, for preventing cytokine storm associated with acute lung injury in COVID-19 patients.
Neptune Wellness Solutions (NASDAQ:NEPT) has filed an application with the FDA to register its Conover, NC facility to prepare alcohol-based hand sanitizers. Shares up 9% premarket.
https://seekingalpha.com/news/3559624-biohaven-on-go-study-of-vazegepant-in-covidminus-19-others-take-action-amid-pandemic

Biohaven on go with study of vazegepant in COVID-19

The FDA has signed off on a Phase 2 clinical trial evaluating intranasal administration of Biohaven Pharmaceutical Holding Company’s (NYSE:BHVN) migraine med vazegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, in COVID-19 patients with pulmonary complications who need supplemental oxygen. Shares up 4% premarket.
The rationale is that the drug may mitigate hyperimmune reactions that could prove fatal in these patients.
https://seekingalpha.com/news/3559624-biohaven-on-go-study-of-vazegepant-in-covidminus-19-others-take-action-amid-pandemic

Fauci hopes to see steps to normalization by summer

Dr. Anthony Fauci, an infectious diseases expert who regularly speaks at the White House coronavirus task force briefings, tells NBC he hopes that steps to normalization will be underway by summer.
Fauci, who is director of the National Institute of Allergy and Infectious Diseases, also said he thinks New York may be beginning to turn the corner and starting to see a flattening of the coronavirus curve.
The U.S. has ~432K confirmed cases of COVID-19 and 14,808 deaths, according to the Johns Hopkins University Coronavirus Resource Center; New York state has 151K of those cases and 6,269 of those deaths.
https://seekingalpha.com/news/3559618-fauci-hopes-to-see-steps-to-normalization-summer-nbc

Pfizer Advances Battle Against COVID-19 on Multiple Fronts

  • Anti-viral compounds show activity against SARS-CoV-2 in preclinical screening
  • Pfizer and BioNTech enter into collaboration agreement to co-develop potential COVID-19 vaccine
  • Company shares additional data and analysis of azithromycin
  • Launch of two new studies to provide insights on the interaction between S. pneumoniae and SARS-CoV-2
  • Pfizer explores studies of JAK inhibitor tofacitinib in patients with COVID-19-related pneumonia

Pfizer Inc. (NYSE: PFE) today announced important advances in the battle against the global COVID-19 pandemic.
As outlined in Pfizer’s five-point plan, the company has been collaborating across the healthcare innovation ecosystem ranging from large pharmaceutical companies to the smallest of biotech companies, from government agencies to academic institutions to address the COVID-19 global health care crisis. Researchers and scientists have been relentlessly working to develop an investigational antiviral compound to treat SARS-CoV-2, which causes the current pandemic of coronavirus infections (COVID-19), a vaccine to prevent infection as well as evaluating other therapies that have scientific potential to help infected patients fight the virus.
“We are committed to making the impossible possible,” said Dr. Albert Bourla, Chairman and CEO. “In the spirit of the Five Point Plan that Pfizer issued, we are facing this public health challenge head on by collaborating with industry partners and academic institutions to develop potential novel approaches to prevent and treat COVID-19. Our researchers and scientists also have been exploring potential new uses of existing medicines in Pfizer’s portfolio to help infected patients globally. We are leaving no stone unturned as we explore every option to help provide society with a treatment or cure.”
Pfizer announced key advances in its commitment to protect humankind from this escalating pandemic and prepare the industry to better respond to future global health crises.
Anti-Viral Compound Screening
Pfizer confirmed a lead compound and analogues are potent inhibitors of the SARS-CoV-2 3C-like (3CL) protease, based on the results of initial screening assays. In addition, preliminary data suggest the lead protease inhibitor shows antiviral activity against SARS-CoV-2. Consequently, Pfizer will perform pre-clinical confirmatory studies, including further anti-viral profiling and assessment of the suitability of the lead molecule for IV administration clinically. In parallel, the company is also investing in materials that will accelerate the start of a potential clinical study of the lead molecule to third quarter 2020, three or more months in advance of earlier estimates, subject to positive completion of the pre-clinical confirmatory studies.
Applying Pfizer’s Long History in Vaccine Research Development Expertise to Finalize Our Agreement with BioNTech
Pfizer Inc. and BioNTech SE have entered into a global collaboration agreement to co-develop BioNTech’s potential first-in-class, mRNA-based coronavirus vaccine program aimed at preventing COVID-19 infection. In March 2020, the companies announced a letter of intent to collaborate and began working together at that time. The two companies plan to jointly conduct clinical trials for the COVID-19 vaccine candidates initially in the United States and Europe across multiple research sites. BioNTech and Pfizer intend to initiate clinical trials as early as the end of April 2020, assuming regulatory clearance. The companies estimate that there is potential to supply millions of vaccine doses by the end of 2020 subject to technical success of the development program and approval of regulatory authorities and then rapidly scale up to capacity to produce hundreds of millions of doses in 2021. For the terms of the agreement, please see the press release page of Pfizer’s website.
Analysis of Azithromycin as an Agent with Antiviral Activity
In an effort to share information that could benefit COVID-19 mitigation efforts, Pfizer researchers will publish a review in Clinical Pharmacology and Therapeutics which assesses published in vitro and clinical data regarding azithromycin as an agent with antiviral properties. This open access review may serve to facilitate the use of azithromycin in future research on COVID-19. Azithromycin is not approved for the treatment of viral infections.
Studying Pfizer’s Existing Medicines for Critical Patient Populations in Need
Pfizer Inc. and the Liverpool School of Tropical Medicine’s Respiratory Infection Clinical Research Group are launching two new studies to provide insights on the interaction between S. pneumoniae and SARS-CoV-2. Pfizer is expected to finalize in the coming days, a research collaboration agreement with Liverpool to provide funding and in-kind laboratory testing support for this research. The studies (SAFER study (SARS-CoV-2 Acquisition in Frontline Health Care Workers – Evaluation to Inform Response) and the FASTER study (Facilitating A SARS CoV-2 Test for Rapid triage)) will help demonstrate whether patients infected with COVID-19 have a higher risk of also developing pneumococcal pneumonia and if having both infections leads to more severe disease and poorer outcomes. The SAFER study will enroll 100 healthcare workers at the Royal Liverpool Hospital and examine rates of SARS-CoV-2 acquisition and dynamics of pneumococcal colonization. The FASTER study will recruit 400 patients from the infectious disease ward at the Royal Liverpool Hospital suspected of having coronavirus. Enrollment has already begun, and data are expected over the next few months.
An independent Phase 2 investigator-initiated study for the use of tofacitinib, an oral Janus Kinase (JAK) inhibitor, in patients with SARS-CoV-2 interstitial pneumonia is planned to be initiated in Italy later this week. The study is supported by a Pfizer grant. For more details about the study, please see clinicaltrials.gov.
Pfizer is also in discussions with other institutions about additional studies involving tofacitinib and potentially other immune modulators in our portfolio. This research is based on the hypothesis that JAK inhibition could mitigate systemic and alveolar inflammation in patients with COVID-19-related pneumonia by inhibiting essential cytokine signaling involved in immune-mediated inflammatory response that could lead to damage of the lungs, resulting in acute respiratory distress syndrome in patients with COVID-19-related pneumonia. It is important to note, tofacitinib is not currently approved for this use and should not be used in patients with an active serious infection.
“While this work can generally take years, we are working to find opportunities to save time wherever we can and work in parallel rather than in a linear capacity,” said Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development & Medical, Pfizer. “This pursuit requires a crucial multi-pronged approach with a deep collaboration and partnership across the health innovation ecosystem – from the academic community, industry partners, policymakers and regulatory bodies. We announced in March that we are collaborating with BioNTech to co-develop a potential first-in-class, mRNA-based COVID-19 vaccine. A public threat like coronavirus COVID-19 pushes each of us to urgently bring forward our resources and expertise to overcome this most challenging moment in the medical history of this century.”
The company will continue to share information from its portfolio and emerging candidates that could benefit the many companies and organizations who are working quickly to provide solutions to combat this unprecedented healthcare crisis.
https://www.marketscreener.com/PFIZER-INC-23365019/news/Pfizer-Advances-Battle-Against-COVID-19-on-Multiple-Fronts-30390638/

IBIO up 26% premarket on advancement of COVID-19 vaccine development

Nano cap iBio (NYSEMKT:IBIO) is up 26% premarket on increased volume in reaction to its announcement that it has inked two Master Services Agreements and a Memorandum of Understanding (MoU) with the Infectious Disease Research Institute (IDRI) aimed at advancing its SARS-CoV-2 Virus-Like Particle vaccine candidate.
Under the agreements, IDRI will support preclinical development and will oversee clinical trials while the company will provide process development and manufacturing services.
The MoU calls for a separate agreement within 60 days between the parties if the company opts to include one of IDRI’s adjuvants in the program (called IBIO-200).
https://seekingalpha.com/news/3559610-ibio-up-26-premarket-on-advancement-of-covidminus-19-vaccine-development